Mizuho has lowered its price target for Waystar Holding Corp. (WAY) to $42 from $50, citing competitive risks in the healthcare technology sector, while maintaining an Outperform rating. Conversely, Leerink initiated coverage with an Outperform rating and a $43 price target, highlighting Waystar’s market reach, improved end-to-end products, and strengthened AI capabilities through the Iodine acquisition. Additionally, Waystar announced the resignation of its Chief Business Officer, Eric Sinclair III, effective March 2, 2026, and showcased its enhanced AltitudeAI system, which has prevented $15.5 billion in claim denials.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
Mizuho Lowers Waystar Holding Corp. (WAY) Price Target to $42 Amid Competitive Healthcare Tech Risks
Mizuho has lowered its price target for Waystar Holding Corp. (WAY) to $42 from $50, citing competitive risks in the healthcare technology sector, while maintaining an Outperform rating. Conversely, Leerink initiated coverage with an Outperform rating and a $43 price target, highlighting Waystar’s market reach, improved end-to-end products, and strengthened AI capabilities through the Iodine acquisition. Additionally, Waystar announced the resignation of its Chief Business Officer, Eric Sinclair III, effective March 2, 2026, and showcased its enhanced AltitudeAI system, which has prevented $15.5 billion in claim denials.